Prosonix reports Phase II COPD data for PSX1002

Prosonix Ltd. (Oxford, U.K.) said single doses of orally inhaled PSX1002 met the primary endpoint of improving forced expiratory volume in 1 second (FEV1) AUC from 0-24 hours post-dose vs. placebo in ...